At Biogen, our mission is clear: we are pioneers in neuroscience. Since our founding in 1978 as one of the world’s first global biotechnology companies, Biogen has led innovative scientific research with the goal over the last decade to defeat devastating neurological diseases.
We believe that no other disease area holds as much need or as much promise for medical breakthroughs as neuroscience. Our focus on neuroscience, our deep scientific expertise and our courage to take risks make us leaders in the research and development of medicines to transform neuroscience to benefit society.
We came to Biogen to solve the unsolvable. We stay to create new possibilities and grow together. We work fearlessly and go beyond because we care deeply about making a difference and changing lives. All legitimate correspondence from a Biogen employee will come from “@biogen.com” or “@smartrecruiters.com” email accounts.
Biogen is a purpose-driven company that pioneers science for the benefit of humanity.
We work to improve patients’ lives and care deeply about making a difference in our society through science that may have the potential to, among other things, improve brain health, mobility and vision. We focus on science that seeks to solve societal problems and create access to innovation. We strive to be leaders by taking meaningful action for the patients we serve, our employees, the environment and the community – including accelerating our efforts in diversity, equity and inclusion. We work with purpose to advance science to address the urgent and long-term challenges facing humanity.
We are responding to stakeholder interests through increasing transparency across our environmental, social and governance (ESG) efforts, including aligning this report with evolving reporting frameworks such as Sustainability Accounting Standards Board (SASB), Task Force on Climate-related Financial Disclosures (TCFD) and Stakeholder Capitalism Metrics, among others. See our Reporting section for more details.
With this Year in Review, we are pleased to report on our purpose-driven performance on material ESG issues and 2020 highlights across our key priorities:
Lauren Work, living with MS, is on a mission to change the narrative of MS and improve health outcomes for underrepresented women.
ESG Governance and Strategy
Guided by our purpose, Biogen has long been committed to leadership in various aspects of corporate responsibility. As part of our commitment, we have tied a portion of our employees’ and executive officers’ 2021 compensation to advancing our ESG strategy.
We believe our governance structures and processes, including our ESG materiality assessment, can strengthen stakeholder relations and help ensure accountability.
Principles, Policies & Positions
We work to create advances in healthcare through pioneering research and global development, manufacturing and commercial capabilities, and upholding our commitment to ethical conduct and overall corporate responsibility.
This commitment is grounded in our Code of Business Conduct, which applies to all employees, agents and consultants acting on behalf of Biogen and affiliates worldwide. We also are guided by a range of principles, policies and positions, including ourGlobal Sustainability Policy and other statements on ethical business conduct, compliance, accountability and transparency, among other topics. To review the full list of our documents, visit our Principles, Policies & Positions.
Responsible and Ethical Supply Chain
All of our suppliers are governed by our Code of Business Conduct and our Anti-Discrimination and Anti-Harassment policy (see our Principles, Policies & Positions). In 2020 we committed to developing a Responsible Supplier Program that will enhance our supplier assessment and due diligence processes and help evaluate the maturity of our suppliers’ ESG efforts such as climate and human rights. Learn more about our supplier human rights screen and our environmental and social assessments by viewing our Year in Review. Learn more about our commitment to addressing climate throughout our supply chain here.
In addition, Biogen’s Supplier Diversity Program ensures that small and diverse business enterprises have an equitable opportunity to compete for Biogen’s business, with supplier diversity integrated into our procurement procedures. We committed to increasing our U.S. minority-owned business spend by 50-100% by 2023, a goal we set as part of our enhanced Diversity, Equity & Inclusion strategy. Learn more about our Diversity, Equity & Inclusion strategy.
We are honored by the recognition we receive and inspired to continue to accelerate our leadership on ESG issues with the aim to catalyze positive change.
In 2020 Biogen was named the #1 biotechnology company on the Dow Jones Sustainability World Index (DJSI World Index) – for an industry-record fifth time. In 2013 Biogen was the first U.S.-based biotech company to appear on the DJSI World Index, making 2020 the eighth consecutive year we have been listed among top corporate performers.
We are equally proud of the numerous other awards, rankings and recognitions we received in 2020. Please read our Year in Review for more information on our awards and recognition.
You are now leaving Biogen’s corporate website.
Third Party Sites
Biogen assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site's endorsement of Biogen or this website.